表皮生长因子受体靶向治疗宫颈癌的研究进展  

Research progress of epidermal growth factor receptor targeted therapy for cervical cancer

作　　者：韩布威 刘洋 刘宁 郝新颖 周丽娜 亓丁 袁梦珂 刘丽[2] HAN Buwei;LIU Yang;LIU Ning;HAO Xinying;ZHOU Lina;QI Ding;YUAN Mengke;LIU Li(Graduate School,Heilongjiang University of Chinese Medicine,Heilongjiang Province,Harbin 150040,China;Ward Two,Department of Gynecology,the First Affiliated Hospital of Heilongjiang University of Chinese Medicine,Heilongjiang Province,Harbin 150040,China)

机构地区：[1]黑龙江中医药大学研究生院,黑龙江哈尔滨150040 [2]黑龙江中医药大学附属第一医院妇科二科,黑龙江哈尔滨150040

出　　处：《中国医药导报》2023年第7期50-53,共4页China Medical Herald

基　　金：教育部春晖计划合作科研项目(HLJ2019032)。

摘　　要：宫颈癌的发生普遍与人乳头瘤病毒(HPV)感染有关,而HPV感染与表皮生长因子受体(EGFR)信号级联上调之间存在较大的相关性。因此,EGFR通常被作为靶点并使用酪氨酸激酶抑制剂和单克隆抗体来治疗宫颈癌。本综述旨在整合当代利用EGFR靶向治疗宫颈癌的方法,并强调当前在涉及EGFR突变的宫颈癌中MicroRNA和相关基因的不同作用。对现有的EGFR疗法的潜在耐药性及对更佳疗法的需求进行了回顾和讨论,以期开发出具有更好效果的新型制剂。The occurrence of cervical cancer is generally associated with human papillomavirus(HPV)infection,and there was a strong correlation between HPV infection and epidermal growth factor receptor(EGFR)signaling cascade upregulation.Therefore,EGFR is commonly targeted and used to treat cervical cancer using tyrosine kinase inhibitors and monoclonal antibodies.This review aims to integrate contemporary approaches to EGFR-targeted therapy of cervical cancer and highlight the current differential roles of microRNA and associated genes in cervical cancer involving EGFR mutations.Potential resistance to existing EGFR therapies and the need for better therapies are reviewed and discussed with a view to developing novel agents with better efficacy.

关 键 词：表皮生长因子受体 宫颈癌 人乳头瘤病毒 MIRNA 

分 类 号：R737[医药卫生—肿瘤]